{"id":14978,"date":"2015-07-21T10:40:26","date_gmt":"2015-07-21T09:40:26","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=14978"},"modified":"2015-07-21T10:40:26","modified_gmt":"2015-07-21T09:40:26","slug":"esclerosi-multiple-quins-son-els-nous-tractaments","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","title":{"rendered":"Esclerosis m\u00faltiple: \u00bfcu\u00e1les son los nuevos tratamientos?"},"content":{"rendered":"

La esclerosis m\u00faltiple (EM) es una enfermedad autoinmune del sistema nervioso central que afecta a m\u00e1s de 2 millones de personas en todo el mundo, aproximadamente 630.000 en Europa<\/strong>. En Espa\u00f1a<\/strong>, se calcula que est\u00e1n afectadas alrededor de 46.000 personas, 7.000 en Catalu\u00f1a<\/strong>. En los \u00faltimos a\u00f1os han aparecido nuevos medicamentos para el tratamiento de la EM y, en consecuencia, se han abierto nuevas puertas para convivir con la enfermedad de la mejor forma posible. Estos medicamentos aportan avances en el tratamiento y mejoras en la calidad de vida de los pacientes afectados. La \u00faltima aprobaci\u00f3n del EMA (European Medicines Agency) y la inminente disponibilidad para los pacientes de Catalu\u00f1a de estos nuevos f\u00e1rmacos, ha hecho conveniente una revisi\u00f3n y valoraci\u00f3n de c\u00f3mo quedar\u00e1 el mapa actual y futuro de la EM.<\/p>\n

\u201cEl tratamiento se ha concentrado b\u00e1sicamente en el interfer\u00f3n beta 1b, el interfer\u00f3n beta 1a, el acetato de glatir\u00e1mero, el natalizumab, el fingolimod y la mitoxantrona, medicamentos aprobados y utilizados como tratamientos modificadores de la esclerosis m\u00faltiple con sus ventajas. \u00daltimamente se han comercializado, o est\u00e1n a punto de hacerlo, nuevos medicamentos por v\u00eda oral como el laquinimod, la teriflunomida y el dimetil-fumarato que ofrecen ventajas en su administraci\u00f3n oral, eficacia comparable y efectos adversos individualizados, lo que har\u00e1 que la elecci\u00f3n del tratamiento sea claramente personalizada<\/strong>\u201d explica Tom\u00e0s Casasin, vocal de Hospitales del COFB y coordinador de la actividad.<\/div>\n
\"novetats-esclerosi-multiple<\/a>
Sergio Mart\u00ednez, neur\u00f3logo jefe de secci\u00f3n y responsable de la Unidad de Esclerosis M\u00faltiple del Hospital Universitari Bellvitge<\/figcaption><\/figure>\n

Para profundizar en el conocimiento de las nuevas terapias para combatir la EM, conocer los aspectos cient\u00edficos m\u00e1s relevantes de los nuevos f\u00e1rmacos y revisar la situaci\u00f3n farmacoterap\u00e9utica actual y el futuro de los tratamientos, as\u00ed como dar a conocer el an\u00e1lisis farmacoecon\u00f3mico de los tratamientos actuales, Colegio, conjuntamente con Sociedad Catalana de Farmacia Cl\u00ednica (SCFC), organizaron el 4 de junio la conferencia "Nuevos tratamientos de la esclerosis m\u00faltiple", dirigida a farmac\u00e9uticos de hospital, de atenci\u00f3n primaria y administraci\u00f3n sanitaria.<\/p>\n

\"novetats-esclerosi-multiple<\/a>
Albert Saiz, neur\u00f3logo responsable de la Unidad de Esclerosis M\u00faltiple del Hospital Cl\u00ednic Barcelona<\/figcaption><\/figure>\n

Para tratar estos temas, el doctor Albert Saiz, neur\u00f3logo responsable de la Unidad de Esclerosis M\u00faltiple del Hospital Cl\u00ednic Barcelona, y el doctor Sergio Mart\u00ednez, neur\u00f3logo jefe de secci\u00f3n y responsable de la Unidad de Esclerosis M\u00faltiple del Hospital Universitario Bellvitge, presentaron la situaci\u00f3n actual del tratamiento de la esclerosis m\u00faltiple y analizaron la aparici\u00f3n de los nuevos tratamientos. \u201cUno de los puntos m\u00e1s interesantes fue el diferenciar entre los efectos sobre la disminuci\u00f3n de los brotes de la enfermedad, las lesiones inflamatorias en resonancia, pero sobre todo la variable principal como es el grado de dependencia de los pacientes<\/strong>\u201d concreta Casasin. Tras estas intervenciones, se abri\u00f3 un interesante debate moderado por Julio Mart\u00ednez, presidente de la Sociedad Catalana de Farmacia Cl\u00ednica.<\/p>\n

\"novetats-esclerosi-multiple<\/a>
Pere Ventanyol, farmac\u00e9utico jefe de secci\u00f3n del Hospital Universitario de Son Espases<\/figcaption><\/figure>\n

Por \u00faltimo, Pere Ventanyol, farmac\u00e9utico jefe de secci\u00f3n del Hospital Universitario de Son Espases, habl\u00f3 ampliamente de los informes de posicionamiento terap\u00e9utico del Ministerio de Sanidad con las carencias de evaluaciones farmacoecon\u00f3micas claras y tambi\u00e9n de la importancia del an\u00e1lisis de n\u00famero de pacientes a tratar (NNT) en estos an\u00e1lisis. Asimismo, profundiz\u00f3 en el concepto de a\u00f1os de vida ganados de calidad (AVAC) como modelo econ\u00f3mico m\u00e1s sofisticado pero que da respuesta a los datos de efectividad de las intervenciones sanitarias aplicadas a una determinada poblaci\u00f3n.<\/p>\n

 <\/p>\n

\"novetats-esclerosi-multiple<\/a>
De izquierda a derecha: Tom\u00e1s Casasin (COFB), Sergio Mart\u00ednez, Albert Saiz, Julio Mart\u00ednez (SCFC) y Pere Ventanyol<\/figcaption><\/figure>\n

\u00a0Con la colaboraci\u00f3n de:<\/b><\/p>\n

\"genzyme\"<\/a><\/p>","protected":false},"excerpt":{"rendered":"

La esclerosis m\u00faltiple (EM) es una enfermedad autoinmune del sistema nervioso central que afecta a m\u00e1s de 2 millones de personas en todo el mundo, aproximadamente 630.000 en Europa. En Espa\u00f1a, se calcula que est\u00e1n afectadas alrededor de 46.000 personas, 7.000 en Catalunya. En los \u00faltimos a\u00f1os han aparecido nuevos medicamentos [\u2026]<\/p>","protected":false},"author":1,"featured_media":14989,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[938,2221,215,480],"class_list":["post-14978","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-atencio-primaria","tag-em","tag-esclerosi-multiple","tag-farmacia-hospitalaria"],"yoast_head":"\nEsclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"L\u2019esclerosi m\u00faltiple (EM) \u00e9s una malaltia autoimmune del sistema nervi\u00f3s central que afecta m\u00e9s de 2 milions de persones a tot el m\u00f3n, aproximadament 630.000 a Europa. A Espanya, es calcula que n\u2019estan afectades al voltant de 46.000 persones, 7.000 a Catalunya. En els \u00faltims anys han aparegut nous medicaments […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-21T09:40:26+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments?\",\"datePublished\":\"2015-07-21T09:40:26+00:00\",\"dateModified\":\"2015-07-21T09:40:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\"},\"wordCount\":705,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"Atenci\u00f3 prim\u00e0ria\",\"EM\",\"esclerosi m\u00faltiple\",\"farm\u00e0cia hospital\u00e0ria\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\",\"name\":\"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2015-07-21T09:40:26+00:00\",\"dateModified\":\"2015-07-21T09:40:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","og_locale":"es_ES","og_type":"article","og_title":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"L\u2019esclerosi m\u00faltiple (EM) \u00e9s una malaltia autoimmune del sistema nervi\u00f3s central que afecta m\u00e9s de 2 milions de persones a tot el m\u00f3n, aproximadament 630.000 a Europa. A Espanya, es calcula que n\u2019estan afectades al voltant de 46.000 persones, 7.000 a Catalunya. En els \u00faltims anys han aparegut nous medicaments […]","og_url":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2015-07-21T09:40:26+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments?","datePublished":"2015-07-21T09:40:26+00:00","dateModified":"2015-07-21T09:40:26+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/"},"wordCount":705,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage"},"thumbnailUrl":"","keywords":["Atenci\u00f3 prim\u00e0ria","EM","esclerosi m\u00faltiple","farm\u00e0cia hospital\u00e0ria"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","url":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","name":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage"},"thumbnailUrl":"","datePublished":"2015-07-21T09:40:26+00:00","dateModified":"2015-07-21T09:40:26+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments?"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"L\u2019esclerosi m\u00faltiple (EM) \u00e9s una malaltia autoimmune del sistema nervi\u00f3s central que afecta m\u00e9s de 2 milions de persones a tot el m\u00f3n, aproximadament 630.000 a Europa. A Espanya, es calcula que n\u2019estan afectades al voltant de 46.000 persones, 7.000 a Catalunya. En els \u00faltims anys han aparegut nous medicaments […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/14978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=14978"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/14978\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=14978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=14978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=14978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}